Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics One Possible Fruit Of FDA-Northeastern Collaboration

Executive Summary

A research collaboration agreement between FDA and Northeastern University could help agency officials understand the mechanisms of action of follow-on biologics, thus easing the way for these products once Congress establishes an approval pathway
Advertisement

Related Content

FDA's Decision-Making Process For ANDA Approval Standards Questioned In Vancomycin Case; Would Process Changes Alter The Outcome?
FDA Immunogenicity Testing Guidance Is High-Wire Act For Brand Industry
FDA Immunogenicity Testing Guidance Is High-Wire Act For Brand Industry
FDA Immunogenicity Testing Guidance Is High-Wire Act For Brand Industry
FDA's Decision-Making Process For ANDA Approval Standards Questioned In Vancomycin Case; Would Process Changes Alter The Outcome?
Merck’s Ambitious Plans For Follow-On Biologics
Merck’s Ambitious Plans For Follow-On Biologics

Topics

Advertisement
UsernamePublicRestriction

Register

PS051932

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel